An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

NCT00141284 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infection
Hepatitis C

Interventions

DRUG: nelfinavir 1,250 mg twice daily
DRUG: Zidovudine 300 mg twice daily
DRUG: Lamivudine 150 mg twice daily

Sponsor

Pfizer